Fresenius SE & Co. KGaA (VIE:FRE2)
Austria · Delayed Price · Currency is EUR | Market Cap | 23.43B -10.2% |
| Revenue (ttm) | 23.28B +3.4% |
| Net Income | 1.52B +35.3% |
| EPS | 2.70 +35.3% |
| Shares Out | n/a |
| PE Ratio | 15.39 |
| Forward PE | 10.87 |
| Dividend | 1.05 (2.37%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | n/a |
| Open | 43.89 |
| Previous Close | 44.21 |
| Day's Range | 43.89 - 44.60 |
| 52-Week Range | 35.24 - 52.76 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial StatementsNews
Fresenius Acquires Remaining 45% Stake In MAbxience For Up To EUR 750 Mln
(RTTNews) - Fresenius SE & Co. KGaA (FRE.DE), a health care company, on Thursday announced that it has acquired the remaining 45% stake in mAbxience Holding S.L. for up to 750 million euros.
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Waltz Health and Fresenius Kabi Expand Direct Access to Biosimilars Through Waltz Connect Platform
Collaboration provides direct access to three competitively priced biosimilars through a transparent pricing model across immunology and inflammatory diseases CHICAGO and LAKE ZURICH, Ill, Sept. 29, 2...
EQS-DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 10.09.2026 / 11:59 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 08.09.2026 / 11:02 CET/CEST The issuer is solely responsi...
All You Need to Know About Fresenius SE & Co. (FSNUY) Rating Upgrade to Buy
Fresenius SE & Co. (FSNUY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q2 2026
Strong Q2 results featured double-digit EPS and EBIT growth, margin expansion, and robust cash flow, prompting an upgrade in full-year EPS guidance to 10%-15%. Growth was broad-based across Kabi, Helios, and MedTech, with innovation and operational execution driving performance.
Fresenius SE & Co. KGaA Slides: Q2 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Fresenius SE & Co. KGaA Earnings release: Q2 2026
Fresenius SE & Co. KGaA released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q2 2026
Fresenius SE & Co. KGaA has published its Q2 2026 quarterly earnings report on August 5, 2026.
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation
BAD HOMBURG, Germany, July 23, 2026 /PRNewswire/ -- The issuer is solely responsible for the content of this announcement. Fresenius is further expanding its access to innovation networks through its ...
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Shares in several European and Asian makers of generic medicines fell after President Trump said the U.S. would place tariffs on such drugs starting in August 2028.
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
Fresenius SE & Co. KGaA Slides: Q1 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Fresenius SE & Co. KGaA Earnings release: Q1 2026
Fresenius SE & Co. KGaA released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q1 2026
Fresenius SE & Co. KGaA has published its Q1 2026 quarterly earnings report on May 6, 2026.
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2025
Strong 2025 results featured 7% organic revenue and double-digit core EPS growth, with robust Q4 performance and improved leverage. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, supported by innovation, digitalization, and disciplined capital allocation.
Fresenius SE & Co. KGaA Shareholder letter: Q4 2025
Fresenius SE & Co. KGaA has published a letter to shareholders covering Q4 2025, which was released on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Earnings release: Q4 2025
Fresenius SE & Co. KGaA released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Slides: Q4 2025
Fresenius SE & Co. KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Fresenius SE & Co. KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Healthcare trends and portfolio focus have driven growth, with streamlined operations, innovation, and disciplined capital allocation improving margins and returns. Key segments like IV generics, nutrition, MedTech, and biosimilars are positioned for further expansion, while regulatory and market shifts are being navigated through targeted investment and digitalization.